Table 4.
Univariable subgroup analysis.
| Univariable subgroup analysis | |||||
|---|---|---|---|---|---|
| hrHPV− subgroup(N = 158) | Lymph node metastasis (LNM) | Disease-specific survival (DSS) | |||
| Variable | Contrast | OR [CI] | p-Value | HR [CI] | p-Value |
| PD-L1 pattern | Negative vs. margin | 1.67 [0.71–3.96] | 0.24 | 1.86 [0.58–5.93] | 0.30 |
| Diffuse vs. margin | 4.18 [1.53–11.43] | <0.01 | 6.19 [2.00–19.22] | <0.01 | |
| Diffuse vs. negative/margin | 3.04 [1.32–7.01] | <0.01 | 4.15 [1.92–8.98] | <0.01 | |
| PD-L1 stroma | Positive vs. negative | 0.98 [0.42–2.27] | 0.95 | 1.42 [0.49–4.15] | 0.52 |
| PD-L1 TIM | Present vs. absent | 1.52 [0.72–3.25] | 0.28 | 1.46 [0.64–3.33] | 0.37 |
| Total classical HLA class I | Partial downregulation vs. normal expression | 2.17 [0.60–7.85] | 0.24 | 0.13 [0.02–1.01] | 0.05 |
| Complete downregulations vs. normal expression | 1.26 [0.31–5.23] | 0.75 | 0.37 [0.08–1.66] | 0.19 | |
| Total non-classical HLA class I | Upregulated vs. normal | 1.84 [0.75–4.55] | 0.15 | 0.59 [0.17–2.07] | 0.41 |
| CD8 intratumoral | Per 100,000 pixels | 0.83 [0.24–2.85] | 0.77 | 0.80 [0.18–3.62] | 0.77 |
| CD8 stromal | Per 100,000 pixels | 0.45 [0.23–0.88] | 0.02 | 0.80 [0.45–1.43] | 0.46 |
| FoxP3 intratumoral | Per 100,000 pixels | 18.21 [0.25–1,345.66] | 0.19 | 22.69 [0.58–891.96] | 0.10 |
| FoxP3 stromal | Per 100,000 pixels | 0.71 [0.22–2.27] | 0.56 | 0.52 [0.12–2.35] | 0.40 |
| T-cell ratio intratumoral | Continuous | 1.00 [0.95–1.05] | 0.96 | 0.93 [0.81–1.05] | 0.24 |
| T-cell ratio stromal | Continuous | 0.95 [0.86–1.04] | 0.24 | 0.99 [0.93–1.06] | 0.74 |
| CD163 intratumoral | High vs. low infiltration | 2.17 [1.10–4.30] | 0.03 | 2.17 [1.10–4.30] | 0.05 |
| CD163 stromal | High vs. low infiltration | 1.43 [0.59–3.48] | 0.44 | 1.23 [0.59–3.48] | 0.44 |
| Usual SCC subgroup(N = 180) | LNM | DSS | |||
| Variable | Contrast | OR [CI] | p-Value | HR [CI] | p-Value |
| High-risk HPV | Negative vs. positive | 1.17 [0.56–2.45] | 0.68 | 4.04 [0.96–17.10] | 0.06 |
| PD-L1 pattern | Negative vs. margin | 1.37 [0.62–3.04] | 0.44 | 1.65 [0.52–5.17] | 0.39 |
| Diffuse vs. margin | 3.17 [1.23–8.18] | 0.02 | 4.22 [1.32–13.45] | 0.02 | |
| Diffuse vs. negative/margin | 2.58 [1.17–5.67] | 0.02 | 3.01 [1.35–6.69] | <0.01 | |
| PD-L1 stroma | Positive vs. negative | 0.79 [0.37–1.68] | 0.54 | 1.12 [0.42–3.00] | 0.82 |
| PD-L1 TIM | Present vs. absent | 2.10 [1.05–4.20] | 0.04 | 1.70 [0.75–3.82] | 0.20 |
| Total classical HLA class I | Partial downregulation vs. normal expression | 1.20 [0.41–3.52] | 0.74 | 0.00 [0.00–0.00] | 0.96 |
| Complete downregulations vs. normal expression | 0.48 [0.13–1.75] | 0.27 | 0.46 [0.10–2.12] | 0.32 | |
| Total non-classical HLA class I | Upregulated vs. normal | 2.14 [0.97–4.75] | 0.06 | 0.59 [0.17–2.08] | 0.41 |
| CD8 intratumoral | Per 100,000 pixels | 1.21 [0.38–3.80] | 0.75 | 0.79 [0.17–3.60] | 0.76 |
| CD8 stromal | Per 100,000 pixels | 0.55 [0.32–0.93] | 0.03 | 0.81 [0.47–1.40] | 0.45 |
| FoxP3 intratumoral | Per 100,000 pixels | 40.50 [0.53–3,085.53] | 0.09 | 19.38 [0.34–1,114.01] | 0.15 |
| FoxP3 stromal | Per 100,000 pixels | 0. 0.59 [0.20–1.74] | 0.34 | 0.69 [0.18–2.74] | 0.60 |
| T-cell ratio intratumoral | Continuous | 0.98 [0.92–1.04] | 0.51 | 0.97 [0.88–1.06] | 0.45 |
| T-cell ratio stromal | Continuous | 0.96 [0.90–1.03] | 0.24 | 0.99 [0.93–1.06] | 0.92 |
| CD163 intratumoral | High vs. low infiltration | 2.36 [1.25–4.48] | <0.01 | 2.28 [1.02–5.11] | 0.05 |
| CD163 stromal | High vs. low infiltration | 2.03 [0.89–4.59] | 0.09 | 1.60 [0.55–4.65] | 0.39 |
OR, odds ratio; HR, hazard ratio; CI, 95% confidence interval for OR/HR; LVI, lymphovascular invasion; hrHPV, high-risk human papilloma virus; HLA, human leukocyte antigen; PD-L1, Programmed death ligand-1; TIM, tumor-infiltrating macrophages; SCC, squamous cell carcinoma; –, excluded from the multivariable model during regression analysis; NA, not applicable.
Bold numbers are statistically significant.